Friday, October 06, 2023 2:28:38 PM
"Conclusions: BRI has Gram-positive in vitro activity; topical BRI 0.5% was minimally irritating; and BRI 0.5% was equally efficacious as VAN in a MRSA keratitis model when the corneal epithelium was removed. "
https://pubmed.ncbi.nlm.nih.gov/26501484/
Adenoviral keratoconjunctivitis is often referred to as epidemic keratoconjunctivits and out breaks are common world wide. While it can produce severe symptoms it usually resolves in a few weeks and unlike bacterial and fungal keratitis it is not a cause of permanent eye damage or visual loss. Infrequently the symptoms can last for a few months.
To the best of my knowledge Brilacidin has not been tested against Adenoviruses.
Your comment regarding the Brilacidin eye drop has validity. Fungal keratitis is becoming more common in the Northern hemisphere as the world wide temperature has increased. Fungal keratitis is much more common in tropical countries and the southern US, especially Florida.
At times fungal keratitis responds poorly to topical anti-fungal medications and has a higher rate of permanent corneal scarring, permanent visual loss and even loss of the eye. Corneal scarring at times requires corneal transplantation to improve vision.
IMO Brilacidin has a high probability of being approved for fungal diseases and fungal keratitis. The topical eye drop could be the first Brilacidin approved treatment in humans.
Antibiotic, antiviral and antifungal eye drops are all prescription and will require full testing. There is no reason to believe Brilacidin as a topical eye drop will ever be released over the counter in the United States.
Many other countries do allow antibiotics and topical antibiotic eye drops to be dispensed without a prescription. I have been told one can go to Tijuana, Mexico and buy antibiotics without prescriptions.
Good luck,Farrell
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM
Avant Technologies to Implement AI-Empowered, Zero Trust Architecture in Its Data Centers • AVAI • Apr 29, 2024 8:00 AM